Occurrence of selected toxicities in 197 patients
| Toxicities evaluated . | No. of patients . | % . |
|---|---|---|
| GU toxicity | ||
| Creatinine increase | 27 | 14 |
| Renal failure | 5 | 3 |
| Incontinence | 4 | 2 |
| Urinary retention | 3 | 2 |
| Proteinuria | 2 | 1 |
| Vaginitis | 2 | 1 |
| GU other | 1 | 1 |
| GI toxicity | ||
| Nausea | 117 | 59 |
| Diarrhea | 107 | 54 |
| Stomatitis/pharyngitis | 79 | 40 |
| Anorexia | 78 | 40 |
| Vomiting | 69 | 35 |
| Constipation/bowel obstruction | 36 | 18 |
| Gastritis/ulcer | 14 | 7 |
| Esophagitis/dysphagia | 8 | 4 |
| Dyspepsia/heartburn | 4 | 2 |
| Taste disturbance | 4 | 2 |
| GI mucositis, NOS | 3 | 2 |
| Ileus | 3 | 2 |
| Salivary changes, NOS | 2 | 1 |
| Colitis | 1 | 1 |
| Dehydration | 1 | 1 |
| Mouth dryness | 1 | 1 |
| GI other | 5 | 3 |
| Liver toxicity | ||
| Bilirubin increase | 49 | 25 |
| Alkaline phosphatase or 5′—nucleotidase increase | 27 | 14 |
| Transaminase increase | 24 | 12 |
| Liver, clinical | 1 | 1 |
| Liver, other | 1 | 1 |
| Lung toxicity | ||
| Dyspnea | 35 | 18 |
| Cough | 22 | 11 |
| Pulmonary edema | 16 | 8 |
| Pneumonitis/infiltrates | 10 | 5 |
| ARDS | 2 | 1 |
| Hiccoughs | 1 | 1 |
| Lung, other | 4 | 2 |
| Metabolic toxicity | ||
| Hypokalemia | 25 | 13 |
| Hypocalcemia | 20 | 10 |
| Hyperglycemia | 11 | 6 |
| Hyponatremia | 10 | 5 |
| Hypomagnesemia | 4 | 2 |
| Hypoglycemia | 1 | 1 |
| Hypophosphatemia | 1 | 1 |
| Hypothyroidism | 1 | 1 |
| Metabolic, other | 1 | 1 |
| Toxicities evaluated . | No. of patients . | % . |
|---|---|---|
| GU toxicity | ||
| Creatinine increase | 27 | 14 |
| Renal failure | 5 | 3 |
| Incontinence | 4 | 2 |
| Urinary retention | 3 | 2 |
| Proteinuria | 2 | 1 |
| Vaginitis | 2 | 1 |
| GU other | 1 | 1 |
| GI toxicity | ||
| Nausea | 117 | 59 |
| Diarrhea | 107 | 54 |
| Stomatitis/pharyngitis | 79 | 40 |
| Anorexia | 78 | 40 |
| Vomiting | 69 | 35 |
| Constipation/bowel obstruction | 36 | 18 |
| Gastritis/ulcer | 14 | 7 |
| Esophagitis/dysphagia | 8 | 4 |
| Dyspepsia/heartburn | 4 | 2 |
| Taste disturbance | 4 | 2 |
| GI mucositis, NOS | 3 | 2 |
| Ileus | 3 | 2 |
| Salivary changes, NOS | 2 | 1 |
| Colitis | 1 | 1 |
| Dehydration | 1 | 1 |
| Mouth dryness | 1 | 1 |
| GI other | 5 | 3 |
| Liver toxicity | ||
| Bilirubin increase | 49 | 25 |
| Alkaline phosphatase or 5′—nucleotidase increase | 27 | 14 |
| Transaminase increase | 24 | 12 |
| Liver, clinical | 1 | 1 |
| Liver, other | 1 | 1 |
| Lung toxicity | ||
| Dyspnea | 35 | 18 |
| Cough | 22 | 11 |
| Pulmonary edema | 16 | 8 |
| Pneumonitis/infiltrates | 10 | 5 |
| ARDS | 2 | 1 |
| Hiccoughs | 1 | 1 |
| Lung, other | 4 | 2 |
| Metabolic toxicity | ||
| Hypokalemia | 25 | 13 |
| Hypocalcemia | 20 | 10 |
| Hyperglycemia | 11 | 6 |
| Hyponatremia | 10 | 5 |
| Hypomagnesemia | 4 | 2 |
| Hypoglycemia | 1 | 1 |
| Hypophosphatemia | 1 | 1 |
| Hypothyroidism | 1 | 1 |
| Metabolic, other | 1 | 1 |
Toxicities were classified according to SWOG criteria for SWOG—9031 and to National Cancer Institute Common Toxicity Criteria version 2.0 for SWOG—9333.
ARDS indicates acute respiratory distress syndrome.